Cerevel Therapeutics Holdings Inc [NASDAQ: CERE] stock went on a downward path that fall over -2.13% on Wednesday, amounting to a one-week price increase of more than 3.57%.
Over the last 12 months, CERE stock rose by 28.30%. The one-year Cerevel Therapeutics Holdings Inc stock forecast points to a potential upside of 10.33. The average equity rating for CERE stock is currently 2.67, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for the stock reached $7.35 billion, with 181.36 million shares outstanding and 87.51 million shares in the current float. Compared to the average trading volume of 1.49M shares, CERE stock reached a trading volume of 4680762 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Cerevel Therapeutics Holdings Inc [CERE]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CERE shares is $45.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CERE stock is a recommendation set at 2.67. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
TD Cowen have made an estimate for Cerevel Therapeutics Holdings Inc shares, keeping their opinion on the stock as Market Perform, with their previous recommendation back on December 08, 2023. While these analysts kept the previous recommendation, JP Morgan raised their target price to Neutral. The new note on the price target was released on November 20, 2023, representing the official price target for Cerevel Therapeutics Holdings Inc stock. Previously, the target price had yet another raise to $33, while Piper Sandler analysts kept a Overweight rating on CERE stock. On August 03, 2023, analysts decreased their price target for CERE shares from 36 to 31.
The Average True Range (ATR) for Cerevel Therapeutics Holdings Inc is set at 0.98 The Price to Book ratio for the last quarter was 13.00, with the Price to Cash per share for the same quarter was set at 4.65.
CERE Stock Performance Analysis:
Cerevel Therapeutics Holdings Inc [CERE] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 3.57. With this latest performance, CERE shares dropped by -0.69% in over the last four-week period, additionally sinking by -4.41% over the last 6 months – not to mention a rise of 28.30% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CERE stock in for the last two-week period is set at 44.41, with the RSI for the last a single of trading hit 43.43, and the three-weeks RSI is set at 44.31 for Cerevel Therapeutics Holdings Inc [CERE]. The present Moving Average for the last 50 days of trading for this stock 41.47, while it was recorded at 40.85 for the last single week of trading, and 36.65 for the last 200 days.
Insight into Cerevel Therapeutics Holdings Inc Fundamentals:
Cerevel Therapeutics Holdings Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 10.22 and a Current Ratio set at 10.22.
Cerevel Therapeutics Holdings Inc [CERE] Institutonal Ownership Details
The top three institutional holders of CERE stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.5034%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $178.43 billion in CERE stocks shares; and BERKSHIRE HATHAWAY INC, currently with $135.36 billion in CERE stock with ownership which is approximately 5.1238%.
